Jubilant Pharmova

₹700 19.9 | 2.9%

WEBSITE BSE:530019 NSE : JUBLPHARMA 10 May, 16:01

Market Cap ₹11150 Cr.

Stock P/E 287.0

P/B 2

Current Price ₹700

Book Value ₹ 343

Face Value 1

52W High ₹724

Dividend Yield 0.71%

52W Low ₹ 318.5

Edit Ratio

Jubilant Pharmova Research see more...

Overview Inc. Year: 1978Industry: Pharmaceuticals & Drugs

Jubilant Pharmova Ltd, previously Jubilant Life Sciences Ltd, is an totally India-based pharmaceuticals corporation. The Company's segments include Contract Research and Development Services, Proprietary Novel Drugs and Pharmaceuticals. The Pharmaceuticals segment operates thru Jubilant Pharma Ltd, that is engaged in manufacturing and supply of Radiopharmaceuticals in the United States, Allergy Therapy Products, Contract Manufacturing of Non-sterile products, Active Pharmaceutical Ingredients, Sterile Injectables and Solid Dosage Formulations. The Contract Research and Development Services segment operates via Jubilant Biosys Ltd, which offers research to global pharmaceutical innovators via studies centers in Bengaluru and Noida in India. Its Proprietary Novel Drugs commercial enterprise via Jubilant Therapeutics Inc., is a patient-centric biopharmaceutical, growing therapies in the area of oncology and auto-immune issues.

Jubilant Pharmova Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Jubilant Pharmova Quarterly Results

#(Fig in Cr.)	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023
Net Sales	1657	1311	1528	1452	1600	1553	1678	1587	1680	1677
Other Income	4	6	-3	11	13	10	4	9	10	36
Total Income	1662	1316	1525	1463	1613	1562	1682	1596	1690	1713
Total Expenditure	1318	1116	1280	1259	1381	1407	1459	1417	1439	1459
Operating Profit	344	200	244	204	232	155	224	178	252	254
Interest	35	37	40	40	42	51	56	62	66	71
Depreciation	100	93	101	95	94	94	271	90	97	95
Exceptional Income / Expenses	0	0	0	0	-57	0	0	0	0	0
Profit Before Tax	209	70	104	69	39	10	-103	27	89	88
Provision for Tax	65	19	47	22	32	25	14	19	36	35
Profit After Tax	144	51	58	47	8	-14	-117	7	53	53
Adjustments	-1	0	2	0	-2	-1	19	-1	9	14
Profit After Adjustments	143	51	60	47	5	-16	-98	6	63	67
Adjusted Earnings Per Share	9	3.2	3.7	3	0.3	-1	-6.1	0.4	4	4.2

Jubilant Pharmova Profit & Loss

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Net Sales	5166	5803	5826	5749	5861	7518	9111	5976	6099	6130	6282	6622
Other Income	30	19	42	13	25	40	36	37	18	11	38	59
Total Income	5196	5822	5869	5763	5886	7558	9147	6013	6116	6141	6320	6681
Total Expenditure	4098	4782	5125	4502	4516	5999	7372	4428	4702	4974	5505	5774
Operating Profit	1098	1040	744	1260	1370	1558	1775	1585	1414	1168	815	908
Interest	311	337	368	371	341	284	220	200	184	145	188	255
Depreciation	254	281	288	347	291	415	371	340	349	382	554	553
Exceptional Income / Expenses	-192	-214	-48	0	0	0	-280	-33	-21	0	-57	0
Profit Before Tax	341	207	40	542	738	859	904	1013	871	630	28	101
Provision for Tax	152	70	80	155	163	225	327	335	297	217	93	104
Profit After Tax	189	138	-40	387	575	634	577	678	574	413	-65	-4
Adjustments	-36	-29	-18	5	1	8	-3	220	262	1	4	41
Profit After Adjustments	153	109	-58	392	576	643	574	898	836	414	-61	38
Adjusted Earnings Per Share	9.6	7.1	-3.6	25.2	37	41.3	36.1	56.4	52.5	26	-3.8	2.5

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	2%	2%	-4%	2%
Operating Profit CAGR	-30%	-20%	-12%	-3%
PAT CAGR	-116%	NAN%	NAN%	NAN%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	105%	-6%	3%	15%
ROE Average	-1%	6%	9%	10%
ROCE Average	3%	8%	10%	11%

Jubilant Pharmova Balance Sheet

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	2476	2627	2454	2966	3436	4087	4809	5604	4741	5319	5399
Minority's Interest	112	158	0	-38	-47	-52	0	0	0	-2	-7
Borrowings	2469	1717	3691	3013	3505	3048	4243	3740	2564	2464	3110
Other Non-Current Liabilities	536	468	345	334	321	370	177	348	409	457	655
Total Current Liabilities	2778	3894	2129	2464	1684	2005	2090	2619	1049	1592	1772
Total Liabilities	8371	8864	8619	8740	8899	9457	11319	12310	8763	9830	10929
Fixed Assets	4967	5099	4911	5104	5107	5401	5648	6340	4609	4871	5183
Other Non-Current Assets	842	837	993	760	844	867	1086	932	1202	1450	1984
Total Current Assets	2561	2928	2715	2875	2948	3190	4585	5038	2953	3509	3762
Total Assets	8371	8864	8619	8740	8899	9457	11319	12310	8763	9830	10929

Jubilant Pharmova Cash Flow

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	263	280	473	392	339	456	244	1005	1231	502	984
Cash Flow from Operating Activities	970	772	783	1099	1268	1303	1122	1543	1784	838	661
Cash Flow from Investing Activities	-500	-174	-343	-313	-450	-618	-1012	-327	-739	-380	-544
Cash Flow from Financing Activities	-450	-414	-503	-843	-686	-901	657	-1050	-1709	-33	-157
Net Cash Inflow / Outflow	20	183	-63	-56	132	-216	767	166	-664	425	-40
Closing Cash & Cash Equivalent	280	473	392	339	456	244	1005	1231	502	984	1014

Jubilant Pharmova Ratios

#	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	9.59	7.06	-3.63	25.22	36.96	41.27	36.07	56.39	52.51	26.01	-3.83
CEPS(Rs)	27.79	27.12	15.56	47.21	55.61	67.37	59.52	63.89	57.98	49.93	30.75
DPS(Rs)	3	3	3	3	3	3	4.5	5	5	5	5
Book NAV/Share(Rs)	155.46	170.07	154.04	190.74	220.61	262.33	301.93	351.83	297.84	333.91	339.04
Core EBITDA Margin(%)	20.21	17.19	11.72	21.16	22.4	20.09	19.09	25.9	22.9	18.86	12.36
EBIT Margin(%)	12.34	9.16	6.82	15.5	17.96	15.13	12.33	20.29	17.3	12.66	3.44
Pre Tax Margin(%)	6.45	3.49	0.67	9.2	12.28	11.37	9.92	16.95	14.28	10.28	0.44
PAT Margin (%)	3.57	2.32	-0.67	6.56	9.57	8.39	6.33	11.34	9.41	6.74	-1.03
Cash Profit Margin (%)	8.37	7.05	4.14	12.45	14.42	13.89	10.4	17.03	15.13	12.96	7.79
ROA(%)	2.34	1.6	-0.46	4.46	6.52	6.91	5.55	5.74	5.45	4.44	-0.63
ROE(%)	7.98	5.39	-1.58	14.28	17.96	16.87	12.97	13.02	11.09	8.21	-1.21
ROCE(%)	10.19	7.92	5.72	12.42	14.44	15.21	13.06	12.2	12.02	9.97	2.53
Receivable days	47	46.53	49.56	54.81	59.43	51.58	48.12	78.33	63.24	52.04	54.89
Inventory Days	73.76	75.51	78.58	75.51	73.64	63.07	56.26	99.64	89.02	70.98	76.57
Payable days	96.31	102.18	98.64	114.98	124.08	120.22	111.74	264.67	191.38	133.47	134.99
PER(x)	17.7	22.51	0	16.51	21.6	20.35	18.42	4.41	12.96	14.91	0
Price/Book(x)	1.09	0.93	0.99	2.18	3.62	3.2	2.2	0.71	2.28	1.16	0.82
Dividend Yield(%)	1.77	1.89	1.97	0.72	0.38	0.36	0.68	2.01	0.73	1.29	1.79
EV/Net Sales(x)	1.28	1.1	1.17	1.85	2.73	2.17	1.54	1.2	2.09	1.32	1.09
EV/Core EBITDA(x)	6	6.12	9.18	8.42	11.69	10.46	7.92	4.54	9.01	6.95	8.39
Net Sales Growth(%)	20.05	12.34	0.39	-1.32	1.95	28.26	21.19	-34.41	2.05	0.52	2.47
EBIT Growth(%)	85.07	-16.51	-25.07	123.95	18.08	5.99	-1.73	7.92	-12.98	-26.46	-72.17
PAT Growth(%)	313.14	-27.09	-129.18	1063.2	48.55	10.41	-9.05	17.46	-15.33	-28.03	-115.71
EPS Growth(%)	948.85	-26.37	-151.37	795.35	46.58	11.64	-12.6	56.35	-6.88	-50.48	-114.74
Debt/Equity(x)	1.71	1.67	1.95	1.52	1.18	0.85	1.01	0.83	0.55	0.55	0.63
Current Ratio(x)	0.92	0.75	1.27	1.17	1.75	1.59	2.19	1.92	2.82	2.2	2.12
Quick Ratio(x)	0.52	0.41	0.69	0.68	1.03	0.9	1.52	1.22	1.74	1.42	1.34
Interest Cover(x)	2.1	1.61	1.11	2.46	3.16	4.02	5.11	6.07	5.73	5.33	1.15
Total Debt/Mcap(x)	1.57	1.74	1.97	0.68	0.32	0.26	0.46	1.17	0.24	0.47	0.77

Jubilant Pharmova Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	50.68	50.68	50.68	50.68	50.68	50.68	50.68	50.68	50.68	50.68
FII	23.18	23.45	23.47	23.06	23.38	23.22	23.2	23.21	20.29	19.06
DII	1.06	0.63	0.62	1.6	1.62	2.86	1.63	1.64	2.89	3.78
Public	25.08	25.25	25.23	24.66	24.33	23.24	24.49	24.48	26.15	26.49
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	8.07	8.07	8.07	8.07	8.07	8.07	8.07	8.07	8.07	8.07
FII	3.69	3.73	3.74	3.67	3.72	3.7	3.7	3.7	3.23	3.04
DII	0.17	0.1	0.1	0.26	0.26	0.46	0.26	0.26	0.46	0.6
Public	4	4.02	4.02	3.93	3.87	3.7	3.9	3.9	4.16	4.22
Others	0	0	0	0	0	0	0	0	0	0
Total	15.93	15.93	15.93	15.93	15.93	15.93	15.93	15.93	15.93	15.93

Pros

Cons

Company has a low return on equity of 6% over the last 3 years.
Debtor days have increased from 133.47 to 134.99days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Jubilant Pharmova News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Jubilant Pharmova

Add Watchlist

Jubilant Pharmova Research see more...

Overview Inc. Year: 1978Industry: Pharmaceuticals & Drugs

Jubilant Pharmova Share Price

Alert Data

Quarterly Price

Peer Comparison

Jubilant Pharmova Quarterly Results

Jubilant Pharmova Profit & Loss

Growth Rates

Jubilant Pharmova Balance Sheet

Jubilant Pharmova Cash Flow

Jubilant Pharmova Ratios

Jubilant Pharmova Shareholding Pattern

Jubilant Pharmova News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!